Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease

Last updated: December 31, 2024
Sponsor: Mostafa Bahaa
Overall Status: Active - Recruiting

Phase

2/3

Condition

Gastrointestinal Diseases And Disorders

Treatment

Mesalamine

Dapagliflozin 10mg Tab

Clinical Study ID

NCT05986136
Tanta 1234
  • Ages 18-60
  • All Genders

Study Summary

The inflammatory bowel diseases (IBD) are described as complex, recurrent inflammatory conditions which are manifested as Crohn's disease (CD) and ulcerative colitis (UC). The common symptoms of IBD include debilitating/severe diarrhea, abdominal pain, weight loss, and chronic fatigue; events that may culminate in life-threatening complications. The pathogenesis of IBD has been characterized as complex/multi-factorial that includes disruption of intestinal epithelial barrier with consequent translocation of commensal microbial products as the prime event that instigates severe immune responses and intestinal inflammation.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age ≥ 18 years

  • Both male and female will be

  • Mild and moderate UC patients diagnosed and confirmed by endoscope

Exclusion

Exclusion Criteria:

  • Breast feeding

  • Significant liver and kidney function abnormalities

  • Colorectal cancer patients

  • Patients with severe UC

  • Patients taking rectal or systemic steroids

  • Patients taking immunosuppressives or biological therapies

  • Addiction to alcohol and / or drugs

  • Known allergy to the dapagliflozin

Study Design

Total Participants: 50
Treatment Group(s): 2
Primary Treatment: Mesalamine
Phase: 2/3
Study Start date:
August 20, 2023
Estimated Completion Date:
July 20, 2028

Connect with a study center

  • Faculty of Medicine, Mansoura University

    Mansoura, 7650001
    Egypt

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.